Article

Acute Psychosis Following Initiation of Ruxolitinib in Post-Polycythaemia Vera Myelofibrosis

2025-08-11

Abstract excerpt

<title>Abstract</title> <p>Polycythaemia vera (PV) is a myeloproliferative neoplasm (MPN) which can progress to myelofibrosis (MF), a phenomenon termed post-PV MF. Ruxolitinib is a Janus activated kinase (JAK) inhibitor that targets JAK mutations and is approved for treatment of high-risk MF. This is a case report of a patient with Post-PV MF who developed acute psychotic disorder five months after commencing rux...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 89a81605-c2bc-5bd8-82b7-c55cc686a155
DOI: 10.21203/rs.3.rs-7291804/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

Acute Psychosis Following Initiation of Ruxolitinib in Post-Polycythaemia Vera MyelofibrosisDOI 10.21203/rs.3.rs-7291804/v1Read

A Case of Concomitant Cryptococcal Meningitis and Anti-NMDA Receptor Encephalitis in a Patient with Myelofibrosis on Ruxolitinib TherapySemantic proximity Read

Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients.Semantic proximity Read

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation.Semantic proximity Read

Emerging treatments for classical myeloproliferative neoplasms.Semantic proximity Read

Pathology consultation on myeloproliferative neoplasms.Semantic proximity Read

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.Semantic proximity Read

JAK2 inhibitors for myeloproliferative neoplasms: what is next?Semantic proximity Read

Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F EraSemantic proximity Read